CLOs on the Move

KSQ Therapeutics

www.ksqtx.com

 
KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ksqtx.com
  • 4 Maguire Road
    Lexington, MA USA 02421
  • Phone: 617.674.9150

Executives

Name Title Contact Details
Kimya Harris
Chief Legal and Administrative Officer Profile

Similar Companies

Datasol

Datasol is a Metuchen, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brain Injury Community

Brain Injury Community is a St Catharines, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

CycleCast

CycleCast makes studio-quality indoor cycling more accessible than ever by delivering hit music and motivational instructors straight to your iPhone. CycleCast works with any indoor bike and brings the energy, intensity, and community of indoor cycling...

Deborah Heart and Lung Center

Deborah Heart and Lung Center was established in 1922 as a tuberculosis sanitarium and pulmonary center. Legend has it that Deborah's rural Burlington County location was the key to recovery because of its therapeutic Jersey pine barren air.

Clinipace

At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.